Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

Launched by STANFORD UNIVERSITY · Jun 11, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for craniofacial pain, which includes conditions like migraines and cluster headaches. The researchers want to see if an injection of a medication called Exparel, delivered through a minimally invasive procedure, can help relieve this type of pain. Exparel has been shown to provide pain relief for up to 72 hours when used in surgical settings. In this trial, participants will be randomly assigned to receive either the Exparel injection or a placebo (a treatment that looks the same but has no active medication) to compare the effects.

To be eligible for this trial, participants should be between the ages of 18 and 80 and have a primary complaint of craniofacial pain, as confirmed during a visit to the clinic. Individuals who are pregnant, have certain allergies, or are unable to provide informed consent will not be included. Those who participate can expect to receive either the Exparel injection or the placebo, and they will be monitored for changes in their pain and overall function. This study is currently recruiting participants, and it's an important step in finding new ways to help those suffering from craniofacial pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a chief complaint of craniofacial pain (migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal hemicrania) who has Stanford Pain \& ENT clinic visit
• Exclusion Criteria:
• • age \<18 or \>80
• • pregnant women
• • economically disadvantaged (not able to afford clinic visits/treatments)
• • decisionally impaired (unable to obtain informed consent)
• • has allergy to bupivacaine
• • unable or unwilling to participate plans to participate in another clinical study at any time during this study